Response Biomedical Corp.

Response Biomedical Corp. is a Canadian company based in Vancouver, British Columbia, that develops and manufactures rapid diagnostic testing solutions for acute care settings. Founded in 1992, the company employs around 66 people and generates annual revenues of approximately $11.8 million. The flagship product, the RAMP® system, is a rapid diagnostics platform that provides lab-quality performance at the point of care. This platform supports a wide range of immunoassays and diagnostic tests, addressing critical areas such as cardiovascular diseases, infectious diseases, and biodefense. Key offerings include test kits for D-dimer, proBNP, Troponin I, COVID-19 Antigen, and various arbovirus panels, among others. Response Biomedical also provides quality control products and point-of-care instruments that integrate with their testing cards. The company aims to improve patient outcomes globally by delivering rapid and accurate diagnostic results, enabling quick decision-making in acute care environments. Under the leadership of CEO Dr. Barb Kinnaird, Response Biomedical is committed to innovation and expanding its global reach through a network of distributors.

• Employees 69
• Founded 1991
• Annual Revenue $5301000
• Total Funding $19965190